{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:48Z","timestamp":1763706588071,"version":"3.44.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1053\/j.seminhematol.2023.06.005","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T02:54:53Z","timestamp":1687920893000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical applications of circulating tumor DNA in Hodgkin lymphoma"],"prefix":"10.1053","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-8504","authenticated-orcid":false,"given":"Jan-Michel","family":"Heger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Ferdinandus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Mattlener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2023.06.005_bib0001","unstructured":"Society AC. Key Statistics for Hodgkin Lymphoma [Internet]. [cited 2023 Mar 13]. Available from: https:\/\/www.cancer.org\/cancer\/hodgkin-lymphoma\/about\/key-statistics.html, accessed 28.03.2023."},{"issue":"7","key":"10.1053\/j.seminhematol.2023.06.005_bib0002","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.06.005_bib0003","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0004","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(16)30093-6","article-title":"Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group","volume":"17","author":"Kreissl","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0005","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"123","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41375-018-0240-8","article-title":"Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)","volume":"33","author":"Borchmann","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.06.005_bib0008","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/annonc\/mdz168","article-title":"Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials","volume":"30","author":"Borchmann","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0009","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.06.005_bib0010","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.22.02473","article-title":"The advanced-stage Hodgkin lymphoma international prognostic index: development and validation of a clinical prediction model from the HoLISTIC consortium","volume":"41","author":"Rodday","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0011","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0012","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography\u2013guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0013","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0014","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1053\/j.seminhematol.2023.06.005_bib0015","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1158\/1078-0432.CCR-22-0433","article-title":"Circulating tumor DNA\u2013based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib, and venetoclax","volume":"28","author":"F\u00fcrstenau","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.06.005_bib0016","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0017","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","author":"Vandenberghe","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.06.005_bib0018","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1182\/bloodadvances.2020003039","article-title":"The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA","volume":"5","author":"Buedts","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.06.005_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3324\/haematol.2020.268813","article-title":"Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential","volume":"107","author":"Raman","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.06.005_bib0020","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"issue":"22","key":"10.1053\/j.seminhematol.2023.06.005_bib0021","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.06.005_bib0022","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","article-title":"Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma","volume":"34","author":"Desch","year":"2020","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0023","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.06.005_bib0024","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.06.005_bib0025","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood-2022-164744","article-title":"Distinct Molecular Subtypes of classic Hodgkin lymphoma identified by comprehensive noninvasive profiling","volume":"140","author":"Alig","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.06.005_bib0026","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood-2022-159230","article-title":"Viral cfDNA profiling reveals distinct EBV subtypes and stratifies risk in Hodgkin lymphomas","volume":"140","author":"Garofalo","year":"2022","journal-title":"Blood"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2023.06.005_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.HS9.0000890716.40811.13","article-title":"P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma","volume":"6","author":"Mammadova","year":"2022","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0028","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin's lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nature Rev Cancer"},{"issue":"17","key":"10.1053\/j.seminhematol.2023.06.005_bib0029","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"John","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.06.005_bib0030","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Andreas","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.06.005_bib0031","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.06.005_bib0032","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.06.005_bib0033","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.15566","article-title":"Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom","volume":"184","author":"Br\u00f6ckelmann","year":"2019","journal-title":"Brit J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.06.005_bib0034","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron emission tomography\u2013driven strategy in advanced Hodgkin lymphoma: prolonged follow-up of the AHL2011 phase III lymphoma study association study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0035","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.06.005_bib0036","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response\u2013adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.06.005_bib0037","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1007\/s00259-021-05403-2","article-title":"Moving the goalposts while scoring\u2015the dilemma posed by new PET technologies","volume":"48","author":"Rogasch","year":"2021","journal-title":"Eur J Nucl Med Mol I"},{"issue":"9976","key":"10.1053\/j.seminhematol.2023.06.005_bib0038","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.06.005_bib0039","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group Phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.06.005_bib0040","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1016\/S2352-3026(18)30140-6","article-title":"Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials","volume":"5","author":"von","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.06.005_bib0041","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.06.005_bib0042","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2022-165917","article-title":"Treatment related morbidity in patients with classical Hodgkin lymphoma: results of the ongoing, randomized phase III HD21 trial by the German Hodgkin Study Group","volume":"140","author":"Borchmann","year":"2022","journal-title":"Blood"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2023.06.005_bib0043","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.HS9.0000890628.71833.65","article-title":"P015: Real World Escalated BEACOPDac delivers similar outcomes to escalated BEACOPP while potentially reducing haematopoietic and reproductive toxicity","volume":"6","author":"Santarsieri","year":"2022","journal-title":"Hemasphere"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.06.005_bib0044","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Medicine"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0045","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.06.005_bib0046","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.06.005_bib0047","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.06.005_bib0048","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2023.06.005_bib0049","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"28","key":"10.1053\/j.seminhematol.2023.06.005_bib0050","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2023.06.005_bib0051","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.06.005_bib0052","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.005_bib0053","doi-asserted-by":"crossref","DOI":"10.1002\/hon.74_2879","article-title":"Nivolumab for relapsed or refractory (R\/R) classical Hodgkin lymphoma (CHL) after autologous transplantation: 5-year overall survival from the phase 2 checkmate 205 study","volume":"39","author":"Ansell","year":"2021","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.06.005_bib0054","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/nprot.2014.170","article-title":"Detecting ultralow-frequency mutations by Duplex Sequencing","volume":"9","author":"Kennedy","year":"2014","journal-title":"Nat Protoc"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:31Z","timestamp":1758522511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196323000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0037196323000513"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.06.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical applications of circulating tumor DNA in Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}